BridgeBio announces results from Phase 2 study of encaleret

BridgeBio (BBIO) Pharma announced that encaleret showed parathyroid hormone-independent normalization of blood and urine calcium in post-surgical hypoparathyroidism. The Phase 2 results were shared in an oral presentation at the American Society for Bone and Mineral Research, ASBMR, Annual Meeting 2025. The Phase 2 proof-of-concept study evaluated the PTH-independent effects of encaleret on renal calcium handling in patients with post-surgical hypoparathyroidism. Ten participants with post-surgical hypoparathyroidism were administered encaleret at 162 mg twice daily for up to 5 days. Calcitriol was stopped one day prior to the first dose. After starting encaleret, calcium and calcitriol were titrated based on blood calcium. The findings from the study include: Encaleret treatment resulted in a rapid and sustained reduction in fractional excretion of calcium in nine participants with post-surgical hypoparathyroidism; 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and urine calcium in the normal reference range within 5 days of treatment initiation compared to 0% of participants on conventional therapy at baseline; These results support the continued evaluation of encaleret as an orally-administered treatment option for patients with chronic hypoparathyroidism.